Daniel Bensen - 27 Mar 2023 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Chief Operating Officer
Signature
/s/ Ali D. Fawaz, Attorney-in-Fact
Issuer symbol
TYRA
Transactions as of
27 Mar 2023
Net transactions value
-$209,478
Form type
4
Filing time
29 Mar 2023, 19:53:04 UTC
Previous filing
23 Mar 2023
Next filing
03 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Options Exercise $4,909 +8,048 +1.5% $0.6100* 536,029 27 Mar 2023 Direct
transaction TYRA Common Stock Sale $128,768 -8,048 -1.5% $16.00 527,981 27 Mar 2023 Direct F1
transaction TYRA Common Stock Options Exercise $2,041 +3,346 +0.63% $0.6100* 531,327 28 Mar 2023 Direct
transaction TYRA Common Stock Sale $53,536 -3,346 -0.63% $16.00 527,981 28 Mar 2023 Direct F1
transaction TYRA Common Stock Options Exercise $1,334 +2,187 +0.41% $0.6100* 530,168 29 Mar 2023 Direct
transaction TYRA Common Stock Sale $35,459 -2,187 -0.41% $16.21 527,981 29 Mar 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -8,048 -3.3% $0.000000 239,354 27 Mar 2023 Common Stock 8,048 $0.6100 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -3,346 -1.4% $0.000000 236,008 28 Mar 2023 Common Stock 3,346 $0.6100 Direct F2
transaction TYRA Stock Option (Right to Buy) Options Exercise $0 -2,187 -0.93% $0.000000 233,821 29 Mar 2023 Common Stock 2,187 $0.6100 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022.
F2 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter.